|Bid||86.62 x 1100|
|Ask||88.20 x 900|
|Day's range||86.89 - 88.03|
|52-week range||79.09 - 95.17|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||8.57|
|Forward dividend & yield||3.33 (3.82%)|
|Ex-dividend date||08 Mar 2022|
|1y target est||102.00|
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.
Swiss drugmaker Novartis (NYSE: NVS) boasts a $207 billion market capitalization, which makes it the sixth-largest pharma stock in the world and the largest international-based pharma stock. Here are a few reasons income investors should consider adding this stock to their portfolios. Novartis had a decent second quarter for the period ended June 30.